Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?

Study reveals that 1 in 10 will initiate opioid prescriptions long term.

2025-09-08

(Press-News.org) New research indicates that many patients who undergo surgery with the intent to cure early-stage cancer continue or start opioid prescriptions in the year following surgery. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

Pain management is essential during cancer care, but prescription opioid practices associated with cancer treatment may lead to unsafe long-term opioid use and adverse outcomes such as opioid use disorder and opioid overdose. To assess the situation, investigators examined rates of new persistent opioid use in the year following surgery for stage 0 to 3 cancers among 9,213 U.S. Veterans who were opioid-naïve (not on prescribed opioids the year prior to their cancer diagnosis).

The team found that potentially dangerous co-prescription of opioid and benzodiazepine (a central nervous system depressant that treats anxiety, insomnia, and seizures and should not be combined with opioids) medications occurred in 366 (4.0%) Veterans during follow-up. Persistent opioid use occurred in 981 (10.6%). A higher intensity of exposure to opioid prescriptions during treatment was associated with these outcomes. People with a prior history of chronic pain, greater comorbidities, lower socioeconomic status, and who received adjuvant chemotherapy were at especially high risk of opioid use in the year after surgery.

“Minimizing opioid exposure associated with cancer treatment while providing effective pain control will decrease long-term health risks among cancer survivors,” said lead author Marilyn M. Schapira, MD, MPH, of the University of Pennsylvania. “This is important as many patients are living longer after a cancer diagnosis and treatment.”

Additional information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER Newsroom upon online publication. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com

Full Citation:
“The Impact of Opioid Use Associated with Curative Intent Cancer Surgery on Safe Opioid Prescribing Practice among Veterans: An Observational Study.” Marilyn M. Schapira, Sumedha Chhatre, Patience M. Dow, Charles E. Leonard, Peter Groeneveld, Jason Prigge, Christopher Roberts, Zachary Meisel, Ravi B. Parikh, Ravishankar Jayadevappa, Emily C. Paulson, Robert Krouse, Katie J. Suda, Pallavi Kumar, Visala Muluk, and Rebecca Hubbard. CANCER; Published Online: September 8, 2025 (DOI: 10.1002/cncr.70009).
URL Upon Publication: http://doi.wiley.com/10.1002/cncr.70009

Author Contact: Meagan Raeke, Senior Science Communications Officer at the Perelman School of Medicine, University of Pennsylvania Health System, at meagan.raeke@pennmedicine.upenn.edu or +1 267-693-6224

About the Journal    
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow CANCER on X @JournalCancer and Instagram @ACSJournalCancer, and stay up to date with the American Cancer Society Journals on LinkedIn.

About Wiley     
Wiley is a global leader in authoritative content, data-driven insights, and knowledge services that advance science and learning. For more than 200 years, we’ve empowered researchers, learners and institutions worldwide to drive progress and solve the world’s most pressing challenges. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.

END

ELSE PRESS RELEASES FROM THIS DATE:

Black youth, especially Black girls, use mental health services less than their White peers

2025-09-08

Black adolescents with mental distress are less likely to use mental health services than their White peers, and Black girls are the least likely to access care, according to new research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241733. “Adolescence is a crucial developmental stage and a critical period for onset of mental health problems,” writes Mercedes Sobers, a PhD candidate in epidemiology at the Dalla Lana School of Public Health, University of Toronto and research coordinator at the Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, ...

Canada must protect youth from sports betting advertising

2025-09-08

Canada must enact strong, effective legislation to protect youth from gambling advertising. Minors are suffering harms from problem gambling despite age restrictions, argue authors in an editorial in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251227 . Since 2021, ads for sports betting have saturated sports broadcasts, constantly viewed by children. Gambling is normalized as a natural part of spectatorship at a young age. Even before single-game sports betting was legalized, a 2019 survey of Canadian students in grades 7–12 found about 4% of students ...

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

2025-09-07

First-in-Human Trial Shows Promising Results for DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer (Barcelona, Spain Sunday, September 7, 2025 at 4:45 PM CEST / UTC +2) — A first-in-human Phase 1 study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in patients with relapsed small cell lung cancer (SCLC). The results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). According to the International Agency for Research on Cancer, ...

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

2025-09-07

(Barcelona, Spain. September 7, 2025 at 4:45 PM CEST / UTC +2 )--Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain. New data from the Phase 2 IDeate-Lung01 trial in 137 patients who had received ≥1 prior line of platinum-based chemotherapy showed a confirmed objective response rate (ORR) of ...

Higher blood pressure in childhood linked to earlier death from heart disease in adulthood

2025-09-07

Research Highlights: Children who had higher blood pressure at age 7 were more likely to die early from cardiovascular disease by their mid-50s. The risk was highest for children whose blood pressure measurements were in the top 10% for their age, sex and height. Both elevated blood pressure (90-94th percentile) and hypertension (≥95th percentile) were linked with about a 40% to 50% higher risk of early cardiovascular death in adulthood. Researchers said their findings show why it’s important to regularly check children’s blood pressure and to help them develop heart-healthy habits early that can help lower their ...

AI helped older adults report accurate blood pressure readings at home

2025-09-07

Research Highlights: Use of an AI voice agent to prompt self-reported blood pressure readings helped to improve accuracy of blood pressure measures and patient outcomes in a group of majority ages 65 and older patients with high blood pressure. The study’s findings demonstrate how integrating AI into care can help to improve home blood pressure monitoring and completion rates, which can lead to improved quality outcomes for patients. Note: The study featured in this news release is a research abstract. Abstracts presented at the American Heart Association’s scientific meetings are not peer-reviewed, and the findings are considered preliminary until published ...

High blood pressure in childhood and premature cardiovascular disease mortality

2025-09-07

About The Study: In a large sample of U.S. children born between 1959 and 1966, higher blood pressure (BP) at age 7 was associated with greater risk of premature cardiovascular disease (CVD) mortality. These findings build upon prior research that linked childhood systolic BP with fatal CVD in young adulthood, but that sample had a follow-up duration through a mean age of only 46 years. This study extends that work with follow-up into the mid-50s and demonstrated consistency in the magnitude of the associations within siblings, which mitigates concerns regarding unmeasured confounding due to shared family or lifestyle characteristics. Corresponding ...

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

2025-09-07

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2 ) — Zidesamtinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing, demonstrated clinically meaningful activity and durability in patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who had progressed on prior TKI therapy. ROS1-positive NSCLC occurs in approximately 1–2% of all NSCLC cases. The results from the Phase ...

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

2025-09-07

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2 ) — Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ALK+ NSCLC, according to results from the Phase 3 E4512 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). The trial, conducted within the ALCHEMIST clinical trials program, ...

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

2025-09-07

Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in Patients with EGFR+ NSCLC Following 3rd-Generation EGFR-TKI Therapy (Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) — Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs). Results from the global Phase 3 HARMONi trial were presented today by Jonathan ...

Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: